Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer
Charles C. Guo(The University of Texas MD Anderson Cancer Center), Bogdan Czerniak(The University of Texas MD Anderson Cancer Center)
Cited by 21
Related Papers
Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy
|Communications Biology|2020|170
Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma
|The Journal of Urology|2012|142
Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape
|Clinical Cancer Research|2017|94
Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior
|Scientific Reports|2017|49